Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras–Directed Therapy

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

On the origin of cancer cells

Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425

Pancreatic Cancer

Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202

Tumorigenesis and the angiogenic switch

Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559

On Respiratory Impairment in Cancer Cells

Warburg, O. H. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,472

Targeting RAS signalling pathways in cancer therapy

Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354

Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes

Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804

Addiction to Oncogenes--the Achilles Heal of Cancer

Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,764

Genetics and biology of pancreatic ductal adenocarcinomaPreprint

Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. M., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,611

New approaches and procedures for cancer treatment: Current perspectives

Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841

Innovative approaches for cancer treatment: current perspectives and new challenges

Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 864

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721

Pancreatic Cancer

Maitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707

Cancer treatment therapies: traditional to modern approaches to combat cancers

Kaur, R., Bhardwaj, A., & Gupta, S. K. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 645

Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches

Orth, M., Metzger, P., Gerum, S., Mayerle, J. V., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 523

Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

Strumberg, D., Clark, J. W., Awada, A. H., Moore, M. J., Richly, H., Hendlisz, A., Hirte, H. W., Eder, J. P., Lenz, H., & Schwartz, B. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-426 · Cited by 414

Biology and management of pancreatic cancer

Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2007) · Postgraduate Medical Journal · doi:10.1136/gut.2006.103333 · Cited by 419

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

Sennino, B., Ishiguro‐Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V. J., Tabruyn, S. P., You, W., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 404

Epigenetic diet: impact on the epigenome and cancer

Hardy, T. M., & Tollefsbol, T. O. (2011) · Epigenomics · doi:10.2217/epi.11.71 · Cited by 416

KRAS mutation in pancreatic cancer

Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360

Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway

Gollob, J., Wilhelm, S. A., CARTER, C., & Kelley, S. K. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 368

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336

Stromal biology of pancreatic cancer

Chu, G. C., Kimmelman, A. C., Hezel, A. F., & DePinho, R. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21209 · Cited by 330

Mutant KRAS is a druggable target for pancreatic cancer

Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295

Gene Therapies for Cancer: Strategies, Challenges and Successes

Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 298

KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment

Dias Carvalho, P., Guimarães, C. F., Cardoso, A. P., Mendonça, S., Costa, Â. M., Oliveira, M. J., & Velho, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2084 · Cited by 202

SiRNA Delivery with PEGylated Graphene Oxide Nanosheets for Combined Photothermal and Genetherapy for Pancreatic Cancer

Yin, F., Hu, K., Chen, Y., Yu, M., Wang, D., Wang, Q., Yong, K., Lu, F., Liang, Y., & Li, Z. (2017) · Theranostics · doi:10.7150/thno.17841 · Cited by 201

Radiation-induced EGFR-signaling and control of DNA-damage repair

Rodemann, H. P., Dittmann, K., & Toulany, M. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701769970 · Cited by 201

Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis

Bassères, D. S., Ebbs, A., Levantini, E., & Baldwin, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4290 · Cited by 189

miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras

Shin, K.-H., Bae, S., Hong, H. S., Kim, R. H., Kang, M., & Park, N. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.055 · Cited by 181

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment

Zeitouni, D., Pylayeva‐Gupta, Y., Der, C. J., & Bryant, K. L. (2016) · Cancers · doi:10.3390/cancers8040045 · Cited by 191

Novel Allosteric Sites on Ras for Lead Generation

Grant, B. J., Lukman, S., Hocker, H. J., Sayyah, J., Brown, J. H., McCammon, J. A., & Gorfe, A. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025711 · Cited by 180

Zebrafish Models for Cancer

Liu, S., & Leach, S. D. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130330 · Cited by 180

let-7 MicroRNA Transfer in Pancreatic Cancer-Derived Cells Inhibits In Vitro Cell Proliferation but Fails to Alter Tumor Progression

Torrisani, J., Bournet, B., du Rieu, M. C., Bouisson, M., Souque, A., Escourrou, J. R., Buscail, L., & Cordelier, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.134 · Cited by 160

Targeting the RAS oncogene

Takashima, A., & Faller, D. V. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.764990 · Cited by 140

Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications

Huang, C., Li, M., Chen, C., & Yao, Q. C. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.5.637 · Cited by 130

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J. G., Jiang, R. H. Y., Ayaz, M., Lawrence, H. R., Kennedy, P., & Sebti, S. M. (2018) · Nature Communications · doi:10.1038/s41467-018-07644-6 · Cited by 122

KRas Induces a Src/PEAK1/ErbB2 Kinase Amplification Loop That Drives Metastatic Growth and Therapy Resistance in Pancreatic Cancer

Kelber, J. A., Reno, T. A., Kaushal, S., Metildi, C. A., Wright, T., Stoletov, K. V., Weems, J. M., Park, F. D., Mose, E. S., Wang, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3552 · Cited by 113

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110

Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo

Qiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.357 · Cited by 99

Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

Anthiya, S., Öztürk, S. C., Yanık, H., Tavukçuoğlu, E., Şahin, A., Datta, D., Charissé, K., Moreira, D., Loza, M. I., Calvo, A., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.016 · Cited by 102

GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 92

Combinational therapy: New hope for pancreatic cancer?

Shi, S., Yao, W., Xu, J., Long, J., Liu, C., & Yu, X. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.029 · Cited by 89

p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Wang, F., Qi, X.-M., Wertz, R., Mortensen, M., Hagen, C. E., Evans, J., Sheinin, Y. M., James, M. A., Liu, P., Tsai, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3281 · Cited by 84

Biodegradable Polymer-Coated Multifunctional Graphene Quantum Dots for Light-Triggered Synergetic Therapy of Pancreatic Cancer

Yang, C., Chan, K. K., Xu, G., Yin, M., Lin, G., Wang, X., Lin, W., Birowosuto, M. D., Zeng, S., Ogi, T., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b16168 · Cited by 82

Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors

Kazi, A., Xiang, S., Yang, H., Chen, L., Kennedy, P., Ayaz, M., Fletcher, S., Cummings, C., Lawrence, H. R., Beato, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3399 · Cited by 81

Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras

Eggers, J. P., Grandgenett, P. M., Collisson, E. C., Lewallen, M. E., Tremayne, J. R., Singh, P. K., Swanson, B. J., Andersen, J. M., Caffrey, T. C., High, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2288 · Cited by 81

Molecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis

Mihaljević, A. L., Michalski, C. W., Friess, H., & Kleeff, J. H. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0622-5 · Cited by 83

GLUT-1 Expression in Pancreatic Neoplasia

Baştürk, O., Singh, R. P., KAYGUSUZ, E. I., Balcı, S., Dursun, N., Çulhacı, N., & Adsay, V. N. (2011) · Pancreas · doi:10.1097/mpa.0b013e318201c935 · Cited by 79

Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering RNA

Zhang, Y., Nemunaitis, J. J., Samuel, S. K., Chen, P., Shen, Y., & Tong, A. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1617 · Cited by 80

Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin

Rachagani, S., Senapati, S., Chakraborty, S., Ponnusamy, M. P., Sushil Kumar, K., Smith, L., Jain, M., & Batra, S. K. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.31 · Cited by 77

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally

Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76

The heat shock transcription factor Hsf1 is downregulated in DNA damage–associated senescence, contributing to the maintenance of senescence phenotype

Kim, G., Meriin, A. B., Gabai, V. L., Christians, E., Benjamin, I. J., Wilson, A. A., Wolozin, B. L., & Sherman, M. Y. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00827.x · Cited by 80

VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic

Epstein, R. J. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9071-1 · Cited by 75

Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells

Diep, C. H., Muñoz, R. M., Choudhary, A. K., Hoff, D. D. V., & Han, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2214 · Cited by 74

Photoactivated cationic alkyl-substituted porphyrin binding to g4-RNA in the 5′-UTR of KRAS oncogene represses translation

Faudale, M., Cogoi, S., & Xodo, L. E. (2011) · Chemical Communications · doi:10.1039/c1cc15850c · Cited by 71

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Hofmann, I., Weiss, A., Elain, G., Schwaederle, M. C., Sterker, D., Romanet, V., Schmelzle, T., Lai, A., Brachmann, S. M., Bentires‐Alj, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044146 · Cited by 69

The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells

Xu, D., Allsop, S. A., Witherspoon, S. M., Snider, J. L., Yeh, J. J., Fiordalisi, J. J., White, C. D. B., Williams, D., Cox, A. D., & Baines, A. T. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr007 · Cited by 69

PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer

Liu, S., Ballian, N., Belaguli, N. S., Patel, S. G., Li, M., Templeton, N. S., Gingras, M., Gibbs, R. A., Fisher, W. P., & Brunicardi, F. C. (2008) · Pancreas · doi:10.1097/mpa.0b013e31816a4a33 · Cited by 66

Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression

Jiang, W., Li, H., Liu, X., Zhang, J., Zhang, W., Li, T., Liu, L., & Yu, X. (2020) · Theranostics · doi:10.7150/thno.46642 · Cited by 65

Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics

Cuciniello, R., Filosa, S., & Crispi, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02193-1 · Cited by 68

Aberrant signaling pathways in pancreatic cancer: A two compartment view

McCleary‐Wheeler, A. L., McWilliams, R. R., & Fernández-Zapico, M. E. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20827 · Cited by 69

N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastomaPreprint

Kessler, J. D., Hasegawa, H., Brun, S. N., Emmenegger, B. A., Yang, Z.-J., Dutton, J., Wang, F., & Wechsler‐Reya, R. J. (2009) · Genes & Development · doi:10.1101/gad.1759909 · Cited by 65

KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells

Moran, D. M., Trusk, P. B., Pry, K., Paz, K., Sidransky, D., & Bacus, S. S. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0649 · Cited by 64

Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells

Li, C., Ge, M., Yin, Y., Luo, M., & Chen, D. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1404-x · Cited by 67

Tailoring Ras-pathway—Inhibitor combinations for cancer therapy

Blum, R., & Kloog, Y. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.11.002 · Cited by 66

Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas

Ischenko, I., Petrenko, O., & Hayman, M. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319911111 · Cited by 62

A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review)

Naser, R., Dilabazian, H., Bahr, H., Barakat, A., & El‐Sibai, M. (2022) · Oncology Reports · doi:10.3892/or.2022.8405 · Cited by 59

Targeting signal transduction in pancreatic cancer treatment

Yeh, J. J., & Der, C. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.673 · Cited by 56

Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs)

Koorstra, J.-B. M., Feldmann, G., Habbe, N., & Maitra, A. (2008) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-008-0282-x · Cited by 54

Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine

Yang, C., Chan, K. K., Lin, W.-J., Soehartono, A. M., Lin, G., Toh, H. T., Yoon, H. S., Chen, C., & Yong, K. (2017) · Nano Research · doi:10.1007/s12274-017-1521-7 · Cited by 53

Novel advances in pancreatic cancer treatment

Vulfovich, M., & Rocha-Lima, C. S. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.993 · Cited by 51

Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer

Zeng, L., Li, J., Wang, Y., Qian, C., Chen, Y., Zhang, Q., Wu, W., Zhong, L., Liang, J., Shuai, X., et al. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.08.007 · Cited by 48

Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets

Barresi, V., Musmeci, C., Rinaldi, A., & Condorelli, D. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168875 · Cited by 52

Biodegradable Nanocapsules as siRNA Carriers for Mutant K‐Ras Gene Silencing of Human Pancreatic Carcinoma Cells

Lin, G., Hu, R., Law, W., Chen, C., Wang, Y., Chin, H. L., Nguyen, Q. T., Lai, C. K., Yoon, H. S., Wang, X., et al. (2013) · Small · doi:10.1002/smll.201201716 · Cited by 47

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., & Grossi, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050653 · Cited by 49

Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside

Furukawa, T. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2226-1 · Cited by 45

Assembling Mn:ZnSe quantum dots-siRNA nanoplexes for gene silencing in tumor cells

Wang, Y., Yang, C., Hu, R., Toh, H. T., Liu, X., Lin, G., Yin, F., Yoon, H. S., & Yong, K. (2014) · Biomaterials Science · doi:10.1039/c4bm00306c · Cited by 46

Aggregation-induced emission (AIE) dye loaded polymer nanoparticles for gene silencing in pancreatic cancer and their in vitro and in vivo biocompatibility evaluation

Hu, R., Yang, C., Wang, Y., Lin, G., Qin, W., Ouyan, Q., Law, W., Nguyen, Q. T., Yoon, H. S., Wang, X., et al. (2014) · Nano Research · doi:10.1007/s12274-014-0642-5 · Cited by 44

Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy

Kothari, V., Wei, I. H., Shankar, S., Sundaram, S. K., Wang, L., Ma, L. W., Vats, P., Grasso, C. S., Robinson, D. R., Wu, Y.-M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0336 · Cited by 43

Biodegradable nanoparticle-mediated K-ras down regulation for pancreatic cancer gene therapy

Yang, C., Hu, R., Anderson, T., Wang, Y., Lin, G., Law, W., Lin, W.-J., Nguyen, Q. T., Toh, H. T., Yoon, H. S., et al. (2015) · Journal of Materials Chemistry B · doi:10.1039/c4tb01623h · Cited by 43

Challenges in Ras therapeutics in pancreatic cancer

Choi, M., Bien, H., Mofunanya, A., & Powers, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.015 · Cited by 39

Molecular aspects of carcinogenesis in pancreatic cancer.

Koliopanos, A., Avgerinos, C., Paraskeva, C., Touloumis, Z., Kelgiorgi, D., & Dervenis, C. (2008) · PubMed · Cited by 39

MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo

Vidic, S., Markelc, B., Serša, G., Coer, A., Kamenšek, U., Tevž, G., Kranjc, S., & Čemažar, M. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.87 · Cited by 38

Molecular Biology of Pancreatic Ductal Adenocarcinoma Progression

Rhim, A. D., & Stanger, B. Z. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385233-5.00002-7 · Cited by 39

Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro

Kawasaki, D., Emori, Y., Eta, R., Iino, Y., Hamano, H., Yoshinaga, K., Tanaka, T., Takei, M., & Watson, S. A. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0591-8 · Cited by 37

Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors

Hindriksen, S., & Bijlsma, M. F. (2012) · Cancers · doi:10.3390/cancers4040989 · Cited by 35

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33

Lysophosphatidic Acid Acyltransferase Beta Regulates mTOR Signaling

Blaskovich, M. A., Yendluri, V., Lawrence, H. R., Lawrence, N. J., Sebti, S. M., & Springett, G. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078632 · Cited by 36

Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles

Parvani, J. G., & Jackson, M. W. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0482 · Cited by 35

Carbon Dioxide-Derived Biodegradable and Cationic Polycarbonates as a New siRNA Carrier for Gene Therapy in Pancreatic Cancer

Zhang, X., Lin, Z., Yang, J., Liu, G., Hu, Z., Huang, H., Li, X., Liu, Q., Ma, M., Xu, Z., et al. (2021) · Nanomaterials · doi:10.3390/nano11092312 · Cited by 33

ASalmonellaTyphimurium mutant strain capable of RNAi delivery

Cheng, X., Zhang, X., Zhou, Y., Zhang, C., & Hua, Z. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29185 · Cited by 33

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer

Kazi, A., Chen, L., Xiang, S., Vangipurapu, R., Yang, H., Beato, F., Fang, B., Williams, T. M., Husain, K. M., Underwood, P. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4781 · Cited by 33

Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells

Watnick, R. S., Rodriguez, R. K., Wang, S., Blois, A. L., Rangarajan, A., Ince, T. A., & Weinberg, R. A. (2014) · Oncogene · doi:10.1038/onc.2014.228 · Cited by 33

Ras and Ras mutations in cancer

Rajasekharan, S., & Raman, T. (2013) · Open Life Sciences · doi:10.2478/s11535-013-0158-5 · Cited by 33

Differential Interference of Chlorpromazine with the Membrane Interactions of Oncogenic K-Ras and Its Effects on Cell Growth

Eisenberg, S., Giehl, K., Henis, Y. I., & Ehrlich, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804589200 · Cited by 33

RAS GTPases are modified by SUMOylation

Choi, B. H., Chen, C., Philips, M., & Dai, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23269 · Cited by 32

Genetic and Epigenetic Biomarkers in Cancer

Verma, M., Seminara, D., Arena, F., John, C. S., Iwamoto, K., & Hartmuller, V. W. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256438 · Cited by 32

Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent

Gopinath, G., Sagurthi, S. R., Shyam, P., Achaiah, G., & Krupadanam, G. L. D. (2014) · RSC Advances · doi:10.1039/c4ra09945a · Cited by 31

Silencing KRAS Overexpression in Arsenic-Transformed Prostate Epithelial and Stem Cells Partially Mitigates Malignant Phenotype

Ngalame, N. N. O., Tokar, E. J., Person, R. J., & Waalkes, M. P. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu201 · Cited by 31

Sweating the Small Stuff

Tang, S., Bonaroti, J. W., Unlu, S., Liang, X., Tang, D., Zeh, H. J., & Lotze, M. T. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182854ab0 · Cited by 30

RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research

Chang, H. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701063 · Cited by 30

Biological Approaches to Therapy of Pancreatic Cancer

Wong, H. H., & Lemoine, N. R. (2008) · Pancreatology · doi:10.1159/000151536 · Cited by 29

Molecular Pathology of Pancreatic Cancer: Implications for Molecular Targeting Therapy

Furukawa, T. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.035 · Cited by 30

Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer through GTPase Signaling Pathways

Padavano, J., Henkhaus, R. S., Chen, H., Skovan, B. A., Cui, H., & Ignatenko, N. A. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s29407 · Cited by 28

Genomic alterations in pancreatic cancer and their relevance to therapy

Takai, E., & Yachida, S. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i10.250 · Cited by 27

Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo

Zhu, H., Liang, Z., Ren, X. Y., & Li, T. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.12.3466 · Cited by 28

Pancreatic cancer inhibition by specific knockdown of K-ras mutant allele expression

Bernhard, E. J. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.2.4025 · Cited by 6

Restoration of E-cadherin and apoptosis of human pancreatic cancer cells after RNA inhibition of mutant K-ras

Fleming, J. B., Shen, G., & Brekken, R. A. (2006) · Journal of Surgical Research · doi:10.1016/j.jss.2005.11.293

The effect of targeting mutant k-ras by siRNA on the expression of transforming growth factor beta 1 in human pancreatic cancer cells

Hui, X. (2010) · Modern Digestion & Intervention

Abstract 2137 Evaluating the effect of RNAi silencing on the KRAS translocation in pancreatic Cancer Cells

Edouard, D., Reilly, M., & Roecklein‐Canfield, J. A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.106120

Alterations in the Ha-ras-1 and thep53 pathway genes in the progression ofN-methyl-N-nitrosourea–induced rat mammary tumors

McKenzie, K. E., Armstrong, B. A., Chen, Y., Nagarajan, M., Aldaz, C. M., & Sukumar, S. V. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199710)20:2 · Cited by 8